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Abstract
Mutations in the TRPC6 calcium channel (Transient receptor potential channel 6) gene have been associated with familiar
forms of Focal and Segmental Glomerulosclerosis (FSGS) affecting children and adults. In addition, acquired glomerular
diseases are associated with increased expression levels of TRPC6. However, the exact role of TRPC6 in the pathogenesis of
FSGS remains to be elucidated. In this work we describe the generation and phenotypic characterization of three different
transgenic mouse lines with podocyte-specific overexpression of the wild type or any of two mutant forms of Trpc6 (P111Q
and E896K) previously related to FSGS. Consistent with the human phenotype a non-nephrotic range of albuminuria was
detectable in almost all transgenic lines. The histological analysis demonstrated that the transgenic mice developed a
kidney disease similar to human FSGS. Differences of 2–3 folds in the presence of glomerular lesions were found between
the non transgenic and transgenic mice expressing Trpc6 in its wild type or mutant forms specifically in podocytes. Electron
microscopy of glomerulus from transgenic mice showed extensive podocyte foot process effacement. We conclude that
overexpression of Trpc6 (wild type or mutated) in podocytes is sufficient to cause a kidney disease consistent with FSGS.
Our results contribute to reinforce the central role of podocytes in the etiology of FSGS. These mice constitute an important
new model in which to study future therapies and outcomes of this complex disease.
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Introduction
Focal and Segmental Glomerulosclereosis (FSGS) is a major
cause of end-stage renal disease that is increasing in frequency [1].
Up to a fifth of FSGS affected patients have a high risk for
progression to end-stage renal disease [2]. While the clinical
presentation of FSGS is often heterogeneous, a characteristic early
sign of this glomerular disease constitutes any level of proteinuria
and a ‘‘focal’’ pattern of injury, meaning a few but not all of the
total sampled glomeruli have ‘‘segmental’’ solidification of the tuft
caused by an accumulation of extracellular matrix with obliter-
ation of the capillary lumina (sclerosis) [2]. There are two
subgroups in the classification of the disease: Primary FSGS
(idiopathic) and Secondary FSGS (genetic, virus infection, drug
induced or mediated by adaptive structural–functional responses).
However, a working classification system which recognizes five
histologic subtypes (collapsing, tip, cellular, perihilar and not
otherwise specified (NOS)) can be used in the diagnosis of Primary
and Secundary FSGS. Typical findings which confirm the
diagnosis of FSGS include collapse, hypercellularity, perhilar
hyalinosis, thickened membranes and certainly sclerosis [3].
At ultrastructural levels, normal glomerular function requires
that the major components of the glomerular filter (the endothelial
cells, glomerular basement membrane and podocytes) be intact
and able to provide a filtration barrier. Podocyte foot processes
and the glomerular slit diaphragm conform critical elements of the
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12859glomerular filter [4]. Recent studies in human as well as in mouse
models revealed that podocyte plays a central role in FSGS [5].
Moreover, foot process effacement, which is the stereotypic
response of the podocyte to injury owing to reorganization of
the actin cytoskeleton, is usually a consistent finding in some
histologic subtypes of FSGS [3].
Human genetic studies have helped to identify genes that are
involved in the development of FSGS such as podocyte-specific
gene nephrosis 2 homolog, podocin (NPHS2) [6,7], a-actinin-4
(ACTN4) gene that encodes for a ubiquitously expressed cytoskel-
etal protein [8], Transient receptor potential channel 6 (TRPC6)
gene which encodes for a calcium channel [9,10] and INF2 gene
which encodes a member of the formin family of actin-regulating
proteins [11]. Besides, recently the myosin heavy chain isoform 9
(MYH9) gene has also been described as a major-effect risk gene
among African Americans [12].
TRPC6 is a member of the TRP family of calcium channels that
contains more than 50 members separated in seven subfamilies of
channel subunits that serve a variety of cellular functions [13,14].
TRPC6 leads to the influx of calcium in direct or indirect response
to phospholipase C (PLC)-mediated signals [15,16]. It can also be
directly activatedbyDAG[17,18]. In kidney, TRPC6 is enriched in
the podocyte foot processes and in collecting ducts, it was also found
tobe associated with nephrinandpodocin [10],bothcentralprotein
components of the slit diaphragm.
Initially, six different families were identified with distinct
mutations in TRPC6 gene [9,10], all showing a dominant mode of
inheritance with adult onset of disease (the clinical symptoms
appearing between the third and fourth decade of life) and
importantly, with a variable penetrance. Most recently, a novel
mutation in this gene which causes an early development of FSGS
in children has been discovered [19]. In this report it was also
shown that all mutations are gain-of function mutation by either
transporting more calcium or displaying impaired inactivation.
However, the relevance of TRPC6 for podocyte function, as well
as the signaling pathways and cellular functions altered by the
FSGS-associated TRPC6 mutations remain unknown.
Human and mouse Trpc6 share 93% and 87% of homology at
cDNA and aminoacid level respectively. In order to address the
question whether TRPC6 dysregulation in podocytes is sufficient to
drive development of FSGS, we have generated transgenic mice that
overexpress the wild type protein or two mutated forms (P111Q and
E896K, both previously described in FSGS patients) of Trpc6
channel under the regulation of the human podocin promoter
(pNPHS2), which have been extensively used in other transgenic
mice to direct expression exclusively to the podocytes [20–25].
Characterization of independent transgenic lines showed a significant
increment of albumin/creatinine ratio in urine samples within non
nephrotic levels. Moreover, abnormal glomerular morphology was
observed by PAS staining of kidney from albuminuric transgenic
mice. Finally, electron microscopy of glomeruli from transgenic mice
showed extensive podocyte foot process effacement.
Taking all our results together, we conclude that podocyte
overexpression of wild type Trpc6, as well as both mutated forms
analyzed, is sufficient to cause a kidney disease consistent with
FSGS.
Results
Trpc6-HA wild type and mutated forms associated with
FSGS are stable and presented a correct subcellular
localization
As a first step towards the generation of Trpc6 transgenic mice
we introduced the influenza virus hemaglutinin epitope (HA tag)
in frame into the 39 end of the murine Trpc6 cDNA clone [26] to
be able to distinguish the transgene product from the endogenous
protein. The resulting tagged protein was tested for stability,
subcellular localization and functionality. In order to determine
the generation of the tagged protein product EBNA293 cells were
transiently transfected with the Trpc6-HA cDNA under the control
of the CMV promoter (figure 1A) and 12 h post transfection the
cell lysate was run in a 10% SDS-PAGE gel followed by Western
blot analysis. As can be seen in figure 1B, a band of the expected
molecular weight (,106 KDa) was observed with an anti-HA
antibody in transfected but not in untransfected cell extracts.
Further an antibody against Trpc6 revealed a band in the identical
position that was also observed in untransfected cell extracts. This
result indicates that the HA tag is in frame, that the resulting
protein product is stable and of the expected molecular weight.
The subcellular localization of the modified protein was assayed by
co-transfecting Trpc6-HA and the plasma membrane marker
pDsRed Monomer-F into HeLa cells. Trpc6-HA co-localizes with
the membrane protein, indicative of correct subcellular localiza-
tion (figure 1C). We also tested that the addition of the small HA
tag did not affect the functionality of the Trpc6 channel. Patch-
clamp studies in HEK cells [27] transfected with Trpc6-HA and
activated with OAG showed normal activity as a classical inward
rectifying channel (data not shown) suggesting that the tagged
channel is active.
In order to study two Trpc6 mutant forms previously associated
with FSGS in humans we introduced independently the two
mutations P111Q and E896K by PCR-based mutagenesis into the
Trpc6-HA sequence, as described in materials and methods
(figure 1A). These two mutations have been previously shown to
have a gain of function when compared to the wild type channel
[9,10].
The stability and subcellular localization of the Trpc6-HA
P111Q and Trpc6-HA E896K were validated in vitro by
transfecting EBNA293 cells with the respective cDNA under the
control of the CMV promoter. As can be seen in figure 1B, a band
of the same molecular weight of Trpc6-HA wild type was observed
with anti-HA and anti-Trpc6 antibodies for both mutant forms,
indicating that these mutations do not affect the stability nor the
expected molecular weight of the proteins. The subcellular
localization of the mutated proteins was also assayed by co-
transfecting Trpc6-HA P111Q and E896K independently and
each of them with the plasma membrane marker pDsRed
Monomer-F into HeLa cells. For both mutant forms the anti-
HA signal co-localizes with the membrane marker, indicative of
correct subcellular localization for the mutant forms of Trpc6
(figure 1C).
Generation of podocyte specific Trpc6-HA transgenic
mice
In order to obtain a podocyte specific transgene, the cDNAs of
Trpc6-HA wild type, Trpc6-HA P111Q and Trpc6-HA E896K,
were subcloned independently downstream of the pNPHS2
podocin specific promoter [20] (figure 2A). By pronuclear
microinjection a total of 17, 5 and 6 transgenic mice were
obtained for Trpc6-HA wild type, Trpc6-HA P111Q and Trpc6-
HA E896K, respectively. Two founders were randomly selected
for each transgene and crossed with C57BL/6J wild type mice: for
Trpc6-HA wild type founders 419 and 421, for Trpc6-HA P111Q
founders 615 and 616, and for Trpc6-HA E896K founders 73a
and 75a. The transgene copy number was estimated by Southern
Blot analysis and ranged between 2 and 18 copies in the different
lines (figure 2B). The level of expression of each transgene was
estimated by quantitative real-time PCR of Trpc6 from mRNA
Trpc6 Causes Glomerulopathy
PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e12859Figure 1. Generation and analysis of modified Trpc6 cDNA’s. (A) Schematic representation of the Trpc6 constructs utilized for the in vitro
studies. Chromatograms of mutations C332A and G2683A that generate aminoacid substitutions P111Q and E896K are shown. (B) Lysates from
EBNA293 either untransfected (u/t) or transfected with a plasmid containing Trpc6-HA wt, Trpc6-HA P111Q or Trpc6-HA E896K cDNA were analyzed
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technique [28]. Our results demonstrated that Trpc6 in the
transgenic lines have a 1.4–6 fold of expression when compared to
wild type littermates (figure 2C) (F419=2.0+/20.9; F421=6.2+/
20.6; F615=2.8+/21.5; F616=3.0+/21.6; F73a=2.5+/20.1;
F75a=1.4+/20.1). In order to confirm the translation of
transgenic mRNA the transgenic protein product was detected
by immunoprecipitation (IP) followed by Western blot analysis.
Proteins obtained from a glomeruli enriched fraction (a pool of 8
kidneys for each genotype), were immunoprecipitated with an HA-
antibody as described in materials and methods and run in a 10%
SDS PAGE followed by Western blot analysis. As can be seen in
figure 3A–B, only in the fraction derived from transgenic animals
we detected a specific band against HA with the expected
molecular weight suggesting the correct expression of the
transgenic protein. To further confirm this result and to determine
the podocyte specific expression of the transgenic proteins we
performed co-immunofluorescence of kidney cryostat sections with
an antibody directed against a podocyte-specific marker: synapto-
podin (Synpo) [28] and the anti-HA antibody to detect the
transgenic proteins. As can be seen in figure 3C expression of the
transgene was restricted to glomerular podocytes, as illustrated by
a strong colocalization with the podocyte-specific marker synapto-
podin in all the transgenic lines.
Albuminuria in transgenic mice
Albuminuria/creatininuria levels were used as an initial
screening parameter for glomerular disease in this study. Adult
mice (5–9 month of age) were tested for albuminuria/creatininuria
in instant fresh urine samples. Characterization of the independent
transgenic lines showed an increment of albumin/creatinine ratio
in urine samples within non-nephrotic levels. Several transgenic
lines appeared significantly albuminuric when compared to the
non transgenic littermates (non transgenic: 11.3+/23.0; 419:
41.4+/210.3, P=0.004; 615: 32.0+/212.8, P=0.015; 73a:
31.8+/26.8, P=0.017; 75a: 23.4+/26.6, P=0.05) (figure 4).
To address the penetrance of this phenotype individual mouse
were analyzed and considered proteinuric when the urine
albumin/creatinine levels were higher than the average value of
wild type littermates plus 2 standard deviations. The percentage of
albuminuric mice was different in the individual transgenic lines
ranging from 23–45%.
Structural injuries induced by the expression of Trpc6-HA
wild type or mutants P111Q and E896K in podocytes
To determine whether the increased albuminuria in transgenic
mice was associated with enhanced renal injury, kidneys were
systematically examined for the presence of pathological changes
in the glomerular, vascular, and interstitial compartments in adult
male mice (5–9 month of age). Glomerular lesions in the wild type
group were relatively mild (Table 1). In contrast, kidneys from
transgenic mice showed more severe pathological findings in
glomeruli including hypercellularity, mesangial expansion, and
glomerulosclerosis (figure 5 and Table 1). Overall, all transgenic
mice lines exhibited perihilar hyalinosis, glomerular sclerosis,
glomerular collapse and thickened membrane that are well known
pathological features described in different stages of FSGS. As
shown in Table 1 and figure 5, the severity of renal pathological
abnormalities was significantly increased in transgenic mice
compared to control animals (in all cases P,0.001). On average,
10–30% of the transgenic glomeruli analyzed had lesions.
Tubulointerstitial damage was also observed in transgenic mice
and consisted mainly in tubular atrophy, presence of casts, fibrosis
as well as inflammatory infiltrates. In conclusion, renal injury was
found in all the analyzed lines which support the concept that
podocyte-specific expression of wild type or mutant Trpc6 channel
is sufficient to drive FSGS-like progressive lesions that extend
beyond the level of glomeruli into the tubulo-interstitium.
As ultrastructural changes in podocytes occur at an early stage
in several glomerulopathies, we also performed electron micros-
copy of the transgenic mouse lines at ,3 months of age. We found
normal configuration of podocytes with coordinated interdigitating
pattern of foot processes in control littermates. In contrast, the
Trpc6 transgenic mice revealed extensive foot process effacement
as well as areas with nude glomerular basement membrane where
podocyte detachment has occurred (Figure 6). These findings are
consistent with progressive glomerular disease such as that seen in
human FSGS [29].
Discussion
FSGS is the second leading cause of renal insufficiency,
exceeded only by diabetic nephropathy. In humans, several genes
[6–12] associated with development of FSGS have been identified,
among them the TRPC6 gene. Distinct mutations in TRPC6 were
described in different families all showing a dominant mode of
inheritance with adult onset of disease and variable penetrance
[9,10,19,30]. Recently, mutations in the TRPC6 channel were
found associated with FSGS in non familiar cases, one of them
being of pediatric onset [30]. This paper also described that all
TRPC6 mutations know to date are gain of function mutations
which elevate peak calcium entry or allow the TRPC6 channel to
remain open for larger period of time once activated.
In this report we describe the generation of a mouse model of
FSGS by overexpressing the wild type or mutant forms of calcium
channel Trpc6 exclusively in podocytes. One of our main findings
is that the overexpression of the wild type Trpc6 channel is enough
to produce a pathologic phenotype. This is interesting because
transient overexpression of TRPC6 in the glomerulus leads to an
acute onset of proteinuria [31]. In essence, it is irrelevant if
mutated or increased wild type TRPC6 is present in podocytes as
they both can produce similar phenotypes. This finding raises the
question of whether the common downstream phenomenon of
dysfunctional TRPC6 is largely a calcium level-mediated effect
rather than structural effects of a mutated TRPC6 channel. Future
studies need to clarify if overexpression of genes other than Trpc6
that can also increase podocyte calcium entry will cause similar
phenotypes.
Another example involving enhanced expression of wild type
TRPC6 and disease was found in idiopathic pulmonary arterial
hypertension in humans [32].
Consistent with the phenotype observed in patients with kidney
disease, our Trpc6 transgenic mice presented albuminuria in adult
male mice with variable penetrance observed in the analyzed
transgenic lines. Since the different lines all showed comparable
by Western Blot analysis with an antibody against Trpc6 (top), against HA (middle) and GFP as a transfection control (bottom). (C) In vitro localization
in HeLa cells co-transfected with pDsRed Monomer-F and a plasmid with either Trpc6-HA wt, Trpc6-HA P111Q or Trpc6-HA E896K cDNA were
subjected to immunofluoresce to identify HA (green), and processed for direct fluorescence from the farnesylated protein DsRed Monomer-F (red). A
representative merged picture shows co-localization of both signals at the plasma membrane for all the transfected proteins. Images were obtained
from a confocal microscope (630x).
doi:10.1371/journal.pone.0012859.g001
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PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12859Figure 2. Trpc6-HA transgenes and molecular characterization of transgenic lines. (A) Scheme of the microinjected transgenes Trpc6-HA
wt, Trpc6-HA P111Q or Trpc6-HA E896K and the wild type allele for Trpc6. The complete Trpc6-HA cDNAs were subcloned downstream the pNPHS2
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Furthermore, incomplete proteinuric penetrance was also ob-
served in mice expressing a mutant form of Actn4 [33]. This might
be explained by the influence of the environment and/or genetic
background since it was already proven that combinations of
genetic heterozygosity (bigenic heterozygosity) that alone do not
result in clinical kidney disease could function together to enhance
susceptibility to glomerular damage and FSGS [34]. Moreover,
the phenotype variable penetrance is a well established finding in
humans with FSGS related to TRPC6 mutations, suggesting that
it may contribute to glomerular diseases in a multi-hit setting [30].
The diagnosis of FSGS is based on the clinical findings of
proteinuria and specific histopathological changes, with the
scarring (sclerosis) in scattered regions of the kidney of a portion
of the glomeruli (focal) and limited to one part of the glomerulus
(segmental) [3]. Our results strongly support that familial FSGS
associated with TRPC6 mutants are caused by podocyte
dysfunction. We observed a number of renal pathologic changes
in mice overexpressing Trpc6 in a podocyte-specific manner that
are consistent with different stages of FSGS-like phenotype. These
include focal perihilar hyalinosis, glomerular collapse, increased
mesangial matrix and focal sclerotic glomeruli. This combination
of pathologic and clinical data in addition with the early
ultrastructural abnormalities found, indicates that mice with
podocyte-specific expression of wild type Trpc6 exhibit a
phenotype similar to that seen in humans with a gain of function
mutation in TRPC6.
Several studies have shown the important role of the podocyte
in the etiology of glomerular diseases like FSGS [35,36]. Mouse
knockout models demonstrate that deficiencies of either podocyte-
specific genes, encoding for podocin [37], nephrin [38], and
Neph1 [39] or more ubiquitously expressed genes, encoding for a-
Actn4 [33], CD2AP [40] and Fyn [41] can result in podocyte
dysfunction leading to progressive glomerular disease. Transient
non-directed overexpression of TRPC6 under the regulation of a
CMV promoter leads to an increase of proteinuria in mice,
showing a correlation between TRPC6 expressions and filtering
abnormalities [31]. However, since Trpc6 is ubiquitously ex-
pressed and the reported transient overexpressors do not show any
selectivity our mouse models provide novel tools to study the
contribution of podocyte dysfunction in the pathogenesis of FSGS.
Interestingly, our data shows that podocyte specific Trpc6
manipulations in mice are able to recapitulate the human disease
and therefore indicate that podocyte dysfunction is a central
element in the development of FSGS. Moreover, this work
provides evidence that, in addition to the effects of gain-of-function
mutations in the TRPC6 gene, constant elevated levels of wild-
type TRPC6 protein is equally powerful to trigger podocyte
dysfunction that include not only proteinuria but also FSGS.
Supporting this notion, Mo ¨ller et al. have found a specific increase
in the expression of TRPC6 within the glomerulus and podocytes
in a variety of glomerular diseases, including minimal change
disease, FSGS and membranous nephropathy [31]. Thus, apart
from a mutation in the TRPC6 coding and regulatory regions,
significant changes in the repertoire of factors that regulate its
levels are probably responsible for FSGS and related disorders.
A recent report [42] demonstrates that TRPC6 mutations
previously shown to enhance channel activity lead to enhanced
basal NFAT-mediated transcription in several cell lines, including
cultured podocytes. Activation of NFAT by TRPC6 mutants was
blocked by inhibitors of calcineurin, calmodulin-dependent kinase
II, and phosphatidylinositol 3-kinase thus identifying the activation
of the calcineurin-NFAT pathway as a potential mediator of
FSGS. In this scenario, and taking all into consideration, our
mouse model can be used to test this hypothesis. On the other
hand, the efficiency of antagonists of TRPC channels, i.e. 2APB
and SKF96365, can be explored to reduce the kidney damage
seen in the Trpc6 transgenic mice.
In summary, we have developedtransgenicmicethat overexpress
the wild type or two mutant forms of Trpc6 calcium channel
proteins in a podocyte-specific manner. Our results strongly support
the concept that podocyte dysfunction is the principal cause of
familial FSGS related with TRPC6 mutations. Moreover, they
provide evidence that, in addition to the effects of gain-of-function
mutations in TRPC6, elevated levels of wild type Trpc6 protein are
sufficient to trigger proteinuria, histological and ultrastructural
changes consistent with a FSGS phenotype and podocyte depletion.
Furthermore, our mouse model provides an important tool for
testing novel therapeutic strategies since channel activities are
suitable for manipulations with pharmaceutical drugs that eventu-
ally may aid in the prevention and treatment of this disease.
Methods
Cloning of murine Trpc6-HA cDNA and generation of
Trpc6 mutant forms
The murine Trpc6 cDNA was kindly donated by Dr.
Birnbaumer [26]. In this plasmid we repaired a point mutation
A2615G that caused an aminoacid substitution D872G and we also
simultaneously incorporated the tag hemaglutinin (HA) at the 39
by site directed mutagenesis with the following primers: Pr1
RepHA forward (59-CAA GTA CAA GGA GCT CAG A-39); Pr2
RepHA reverse (59-CTT ATC AAT CTG GGC CTG C-39); Pr3
RepHA forward (59-CAG ATT GAT AAG GAG AGC GA-39);
Pr4 RepHA reverse (59- AAG GAA TTC TTA AGC GTA ATC
TGG AAC ATC GTA TGG GTA TCT GCG GCT TTC CTC
CAG CT-39). The PCR product was subcloned in a pGEMT-Easy
plasmid and subcloned in the donated pCDNA3 Trpc6 through
Swa I and Eco RI restriction sites, resulting with the pCDNA3
Trpc6-HA. To improve the expression of Trpc6-HA in this
pCDNA3 we introduced an alfalfa mosaic virus RNA 4 (AMV
RNA4) 59UTR through Kpn I and Xcm I restriction sites. The
nucleotide substitutions C332A (P111Q) and G2686A (E896K) were
generated independently by site-directed mutagenesis with the
following primers: Pr1 C332A forward (59- AAC AGA CTG ACT
CAC CGG C-39); Pr2 C332A reverse (59-CCA CTT GGA TGT
TGC CAT AT-39); Pr 3 C332A forward (59-CAT CCA AGT GGT
GCG GAA G-39); Pr 4 C332A reverse (59-AAA GCA TCC CCA
ACT CGA GA-39); Pr1 G2686A forward (59-CAA GTA CAA GGA
GCT CAG A-39); Pr 2 G2686A reverse (59-GGA GTT TAT AAC
GGA GAC TT-39); Pr 3 G2686A forward (59-CCG TTA TAA ACT
CCT TGA AG-39); Pr4 G2686A reverse (59-GAG TGT CAT GGA
podocin promoter, as described in the methods section. The localization of the NheI and HindIII sites surrounding exon 2 on genomic DNA
(Endogenous) or the transgene (Transgenes) are depicted. Two distinguishable fragments of 2 or 3.4 kb for the endogenous allele or the transgene,
respectively, could be detected by Southern blot analysis with a probe that hybridizes in exon 2 (open rectangle). (B) Southern blot analysis of
genomic DNA from non transgenic (NT) or transgenic mice (Trpc6-HA wt, Trpc6-HA P111Q or Trpc6-HA E896K) showed the expected pattern with the
designed probe. Transgene copy number for each line was estimated by densitometric analysis with the endogenous Trpc6 gene for normalization.
(C) The glomeruli average expression levels of the transgene by real-time PCR are depicted for each line. Values represent mean +/2 SEM.
doi:10.1371/journal.pone.0012859.g002
Trpc6 Causes Glomerulopathy
PLoS ONE | www.plosone.org 6 September 2010 | Volume 5 | Issue 9 | e12859GCT CGA-39). PCR products were cloned in pGEMT-Easy and
subcloned to plasmid pCDNA3 Trpc6-HA through the Sgr AI/
Xcm I (mutant P111Q) and Swa I/Eco RI (mutant E896K)
restriction sites. The mutations were confirmed by restriction
analysis with Bfi I (mutant P111Q) and Psi I (mutant E896K) and
by direct sequencing.
In vitro studies
To determine the ability of pCDNA3 Trpc6-HA to express the
proteins (wild type or mutant forms) we performed Western blot
analysis. EBNA293 cells were transfected with 1.6 mg of the
corresponding plasmid using Lipofectamine2000. Sixteen hours
post transfection cells were lysed in RIPA buffer containing 1x
Figure 3. Protein expression in transgenic mice. (A) The in vivo Trpc6-HA expression was confirmed by Immunoprecipitation (IP). The IP was
performed from isolated mouse glomeruli (n=8 kidney from each genotype) as described in material and methods. The glomeruli fraction was
loaded into an HA affinity column, and a 30 ml aliquot of the sample which did not bind into the column was loaded in a gel and stained with
Coomassie brilliant blue as a loading control (effluent control) for transgenic and non transgenic samples. (B) 30 ml of each IP sample was run in a SDS
PAGE and a Western blot analysis against HA epitope was performed. (C) Double immunofluorescence of kidney cryosections to detect synaptopodin
(green) and HA (red) for every transgenic line utilized in this study (400x).
doi:10.1371/journal.pone.0012859.g003
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run in a 10% SDS-PAGE, transferred to a 0.2 mm PVDF
membrane, blocked with 5% not fat milk in TTBS (137 mM
NaCl, 0.1% Tween 20 and 20 mM TrisHCl, pH 7.6) and
incubated with rabbit anti-Trpc6 (ab47679 Abcam), 1/1000. After
3 washes of 30 min each with TTBS the membrane was incubated
with HRP-conjugated goat anti rabbit 1/3000 (Pierce) and
visualized with enhanced chemiluminiscence. The PVDF mem-
brane was then stripped, blocked and incubated with a rat anti-
HA antibody 1/5000 (clone 3F10, Roche) overnight at 4uC.
Bound primary antibody was detected with HRP-conjugated goat
anti rat 1/40000 (Pierce) and visualized as described above.
To determine subcellular localization of Trpc6-HA proteins
(wild type or mutated forms) HeLa cells were co-transfected with
pCDNA3 Trpc6-HA (wild type, P111Q or E896K respectively) and
pDsRed Monomer-F (Clontech) using Lipofectamine 2000 as
described above. The cells were fixed 16-20 h postransfection with
PFA 4%. Afterwards, the cells were treated with PBS-TX100
0.1% for 15 min and blocked with PBS-gelatin 0.2% for 1 hour.
Next, HA tag was detected with a rat anti-HA 1/500 (clone 3 F10,
Roche) antibody and with a goat anti rat Alexa Fluor 488
(Invitrogen). Images were captured with a confocal microscope
Zeiss LSM710.
Patch-clamp studies in HEK cells transfected with Trpc6-HA
and activated with OAG was performed as previously described
[27].
Generation and molecular characterization of transgenic
mice
For all the transgene constructs (Trpc6-wild type, Trpc6-HA
P111Q and Trpc6-HA E896K) the CMV promoter was replaced
with the human podocin promoter (NPHS2) [20] (kindly donated
by Dr. Holzman) utilizing the same two step strategy. In the first
step a 1.2 kb Trpc6 Not I fragment (Trpc6-1.2D) was subcloned
downstream the pNPS2 promoter resulting in the pUC19 NPHS2
Trpc6-1.2D plasmid. In the second step, the CMV promoter in the
pCDNA3 Trpc6-HA plasmid was replaced by the pNPHS2
promoter coming from the pUC19 NPHS2 Trpc6-1.2D plasmid
Figure 4. Phenotypic characterization of kidney function in adult transgenic mice. Albuminuria levels (mg/dL) normalized by creatininuria
levels (mg/dL) were tested in male mice at the age of 5–9 months. The number of mice analyzed for each genotype is as follows: non transgenic mice:
n=10, transgenic 419 n=9, 421 n=9, 615 n=3, 616 n=13, 73a n=17, 75a n=9. Data are presented in the bars as mean +/2 SEM. * and ** mean
statistical significance using non transgenic mice as control group with a P value ,0.05 and ,0.01, respectively.
doi:10.1371/journal.pone.0012859.g004
Table 1. Histopathologic injury scores from kidneys of non
transgenic and transgenic mice at 5–9 months of age.
GLOMERULI
TOTAL
SCORE
HC SCL MEM
Non transgenic 1.8+/20.3 0+/200 +/20 1.7+/20.3
Trpc6-HA 419 3.0+/20.3
* 2.3+/20.6
** 0+/20 5.3+/20.8
**
wt 421 2.7+/20.4 2.7+/20.8
** 0+/20 5.4+/21.2
**
Trpc6-HA 615 3.2+/20.3
** 3.7+/20.6
*** 0+/20 6.9+/20.9
***
P111Q 616 2.8+/20.3
* 2.8+/20.6
*** 0+/20 5.6+/20.8
**
Trpc6-HA 73a 2.6+/20.3 3.4+/20.6
*** 0.2+/20.2 6.3+/20.9
***
E896K 75a 4.0+/20
*** 3.9+/20.4
*** 0.6+/20.3 8.4+/20.6
***
Features consistent with a glomerulopathy found in Trpc6-HA wild type (419
and 421) and mutants P111Q (615, 616) and E896K (73a, 75a) transgenic mice
are shown. HC: hypercellularity, SCL: sclerosis, MEM: thickened membranes. The
total scores for all glomerular lesions found in each transgenic line is shown in
the last column. For each genotype the number of adult mice analyzed is as
follows: non transgenic mice: n=9, transgenic 419 n=10, 421 n=7, 615 n=11,
616 n=12, 73a n=11, 75a n=7. Data are presented as mean +/2 SEM.
*; **; ***mean statistical significance using non transgenic as control group with a
P value ,0.05, ,0.01 and ,0.001, respectively.
doi:10.1371/journal.pone.0012859.t001
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pNPHS2 Trpc6-HA wt, P111Q or E896K plasmids respectively.
To confirm the accuracy of the transgenes the plasmids were
sequenced before microinjection.
The transgenes containing the NPHS2 promoter, Trpc6-HA
cDNA (wild type or mutants) and BGH polyadenilation signal
were released from the corresponding pNPHS2 Trpc6-HA plasmid
by digestion with BfuI and purified by gel electrophoresis using the
QIAExII Gel Extraction kit (QIAGEN) and Elutips columns
(S&S).
Pronuclear microinjection into C57B6/6J 6 CBA/J zygotes
was performed with ,500 molecules of each transgene. Two
founders from each transgene were selected for colony expansion
by crossing them with pure C57B6/6J mice to obtain F1 mice. F1
6F1 mating were set up to generate F2 mice that were used for all
the phenotypic characterization. Mice were maintained in a SPF
facility with a 12 h light:dark cycle (lights on at 7 AM, off at 7 PM)
with access to food and water ad lib. All testing procedures were
approved by the CECS Institutional Animal Care and followed
the NIH Guidelines, ‘‘Using Animals in Intramural Research’’.
Genotyping. For all transgenes genomic DNA was isolated
from 14–21 day old mice tails and used for genotypic analysis by
PCR with: Trpc6 exon 8 forward (59-GACACTGTTCTGGG-
CTATCT-39), Trpc6 intron 8 reverse (59-CCCATTTTCCTCTCC
CCACC-39) and Trpc6 39UTR reverse (59-CAGTGTGATGG-
AGCTCGA-39). The amplification reaction was as follows: 95uC
for 5 min (denaturation) followed by 30 cycles of 94uC for 30 sec,
57uC for 45 sec and 72uC for 45 sec, and a final extension step of
72uC for 5 min. The endogenous Trpc6 gene yields a ,530 bp
PCR product while the transgene yields a ,830 bp PCR product.
Southern blot analysis. For all transgenes ten mg of tail
DNA were digested overnight with NheI and HindIII,
electrophoresed through a 1% agarose gel and transferred to a
Hybond C+ membrane by capillarity. A probe that hybridizes to
exon 2 of Trpc6 was generated by PCR with the primers Trpc6
exon 2 forward (59-AACAGACTGACTCACCGGC-39) and Trpc6
exon 2 reverse (59-AAAGCATCCCCAACTCGAGA-39). The PCR
probe was marked with dCTP-aP
32 using the Megaprime
Labeling System (Amersham).
Determination of transcript expression
We obtained a glomeruli-enriched fraction from 3-month old
male mice (n=4 kidneys from each genotype) utilizing a sieving
technique [28]. Total RNA was isolated from these fractions with
TRIzol Reagent (Invitrogen) according to manufacturer’s instruc-
tions. Prior to reverse transcription, RNA samples were treated
with rDNAse I (DNA-free kit, Applied Biosystems). Then cDNA
was syntethized using ImProm-II Reverse Transcription System
(Promega). The possibility of contamination with genomic DNA
from the transgene was eliminated by using rDNAseI and ‘no RT’
controls in the reactions of Real Time PCR. We performed
quantitative Real Time PCR with QUANTIMIX EASY SYG kit
(BIOTOOLS B&M Labs). The primers used for detecting Trpc6
transcript was designed in exon 2 (forward 59-CATCCCA-
GTGGTGCGGAAG-39 and reverse 59-AAAGCATCCCCAAC-
TCGAGA-39). Results were normalized against Gapdh (forward 59-
ACCCAGAAGACTGTGGATGG-39 and reverse 59- CACATT-
GGGGGTAGGAACAC-39). All reactions were performed in
duplicate with the following amplification parameters: 10 min at
95uC, and 40 cycles of 10 s at 95uC, 30 s at 58uC and 30 s at
72uC. Delta Ct method was used to compare the DCt (cycle
threshold) value of transgenic animal samples (Ct of target-Ct of
control transcript) with DCt value of wild type mice samples.
In vivo protein expression analysis
The in vivo Trpc6-HA expression was confirmed by Immuno-
precipitation (IP) and Immunofluorescence analysis in every line.
IP was performed from isolated mouse glomeruli using anti-HA
Immunoprecipitation Kit (Sigma, Cat No. IP0010). Isolation of
glomeruli was obtained by passing kidney tissue (n=8 kidney from
each genotype) through a series of sieves as described [28]. After
IP, a Western blot analysis against HA epitope was performed
(primary antibody Rat anti-HA 1:5000 clone 3F10, Roche).
Bound primary antibody was detected with HRP-conjugated goat
anti rat 1:15000 (Santa Cruz Biotechnology, Cat. No. sc-2032).
To confirm that the expression of the transgene was resctricted
to podocytes, an immunofluoresce analysis against HA epitope was
performed for every line in analysis. Adult mice were perfused with
1x PBS and 4% PFA. Kidneys were dissected and then frozen in
OCT medium. Five mm sections were washed three times (5
minutes each) with 1x PBS and incubated during one hour at
room temperature with blocking solution (1x PBS, 10% NGS,
Figure 5. Histopathological lesions analyzed in adult trans-
genic mice. Representative examples of kidney sections stained with
PAS in 400x for all the samples are shown. (A) Non transgenic mouse
normal glomerulus, (B) Trpc6-HA wt line 419, (C) Trpc6-HA wt line 421,
(D) Trpc6-HA P111Q line 615, (E) Trpc6-HA P111Q line 616, (F) Trpc6-HA
E896K line 73a and (G) Trpc6-HA E896K line 75a. The glomerular lesions
were analyzed in blind by a pathologist and are summarized in Table 1.
doi:10.1371/journal.pone.0012859.g005
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using Super Block and Mouse-to-Mouse Blocking Reagent
according to the manufacturer instructions (ScyTek Laboratories).
Primaries antibodies (prediluted in blocking solution) were
incubated ON at 4uC (Rabbit anti HA 1:300, Bethyl Cat.
No. A190-108A; Mouse anti Synaptopodin 1:80, Progen Cat.
No. 61094). Secondary antibodies were incubated for 40 minutes
at RT (Goat anti Rabbit AF568 1:1000; Goat anti Mouse AF488
1:1000). Finally sections were washed with 1x PBS, rinsed with
water and mounted with Dako Fluorescent Mounting Medium
(Dako). Mounted slides were analyzed with Nikon Eclipse
TE2000-U microscope. Pictures were captured with Q Imaging
Fast 1394 digital camera using QCapture Pro software (Version
6.0.0.412). Merges were digitally processed using Adobe Photo-
shop 11.0.
Phenotypic characterization
In order to minimize the error due to sex or age differences all
the phenotypic characterization was performed in adult male
mice, of 5–9 months of age.
Albuminuria was measured in fresh urine samples. Albuminuria
normalized by creatininuria (mg/mg) was determined as described
previously [43]. The number of mice analyzed for each genotype
was as follows: non transgenic mice: n=10, transgenic 419 n=9,
421 n=9, 615 n=3, 616 n=13, 73a n=17, 75a n=9.
For histopathological analysis mice were transcardially per-
fused with 15 ml room temperature 1x PBS and then 30 ml of
cold 4% PFA. Perfused kidney were dissected, dehydrated in
alcohol gradient and embedded in paraffin. Four mm sections
were used for periodic acid-Schiff reagent (PAS) staining. The
number of mice analyzed for each genotype was as follows: non
transgenic mice: n=9, transgenic 419 n=10, 421 n=7, 615
n=11, 616 n=12, 73a n=11, 75a n=7. All of the samples were
examined by two independent pathologists (Carpio and Ruiz)
without knowledge of the genotypes. The pathological abnor-
malities in the kidney were graded based on the presence and
severity of component abnormalities, including glomerulosclero-
sis, mesangial expansion, chronic inflammation, tubular atrophy
or casts, fibrosis, and vascular injury. Grading for each
component was performed using a semiquantitative scale as
previously described [44] where zero was no abnormality and
where one, two, three, and four represented mild, moderate,
moderately severe, and severe abnormalities, respectively. The
percentage of glomerular abnormalities is defined as the number
of glomeruli with damage divided by the total number of
glomeruli in the section.
For electron microscopy, kidney cortex samples were fixed in
glutaraldehyde 2%. Specimens were rinsed in phosphate buffer,
followed by OsO4, dehydrated in ethanol and acetone and
embedded in Epon resin. Semi-thin sections were dyed with blue
toluidine to evaluate general renal morphology. Afterwards,
ultrathin sections were cut in a Sorvall microtome, incubated in
uranyl acetate and a plumb solution and then visualized with a
Hitachi H700 microscope. Sections were analyzed in blind by a
specialized patho-nephrologist.
Statistical analysis
T-test was performed to determine the statistical significance of
the different parameters presented in this study between each
transgenic line and the control group. Error bars represent
standard errors of the mean. Data are expressed as mean 6 SEM.
Values of P,0.05 were considered to be significant.
Figure 6. Ultrastructural changes in podocytes from Trpc6-HA transgenic mice. Kidney sections from 3 month old non transgenic (top
panel) and transgenic (bottom panel) mice were assessed by electron microscopy. In the top panel an overview of normal mesangium and capillary
loops and filtration barrier with normal foot processes is shown for the non transgenic mice (3000, 6000 and 15,000x respectively). In the bottom
panel it can be observed that extensive foot process effacement of the podocytes are present in the transgenic section (red arrows) (3000, 6000 and
15,000x respectively).
doi:10.1371/journal.pone.0012859.g006
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